Skip to main content

Search Videos and More

Showing 121 - 132 of 162 results

Previous| 1... 10 | 11 | 12 ...14 |Next

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

Although the AHA Guidelines identify a 70 mg/dL threshold target for patients at high risk for recurrent ACS, do you believe this is merely a “starting point” identifying a minimal level of LDL-C goal attainment?

Although the AHA Guidelines identify a 70 mg/dL threshold target for patients at high risk for recurrent ACS, do you believe this is merely a “starting point” identifying a minimal level of LDL-C goal attainment?

In the subpopulation of high-risk patients—individuals with post-ACS, patients with diabetes, post-PCI and others—is there enough compelling evidence from the PCSK9 trials that the “LDL hypothesis” is a proven fact?

In the subpopulation of high-risk patients—individuals with post-ACS, patients with diabetes, post-PCI and others—is there enough compelling evidence from the PCSK9 trials that the “LDL hypothesis” is a proven fact?

Can you cite specific patient types where you are strongly inclined to use a PCSK9 inhibitor because achieving both significant percentage-based reductions in LDL-C level as well as achieving an LDL-C level <70mg/dL are of critical importance?

Can you cite specific patient types where you are strongly inclined to use a PCSK9 inhibitor because achieving both significant percentage-based reductions in LDL-C level as well as achieving an LDL-C level <70mg/dL are of critical importance?

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

With respect to patients with HeFH and homozygous FH who are challenged with lifelong CV disease risk burden due to genetic risk, what role do you believe PCSK9 inhibitors should play, especially in younger patient populations?

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial?

Within the context of the ESC and U.S. guidelines for LDL-C reduction, which recommend 70 mg/dL as a threshold target, how should we view the cholesterol landscape between 20 mg/dL and 70 mg/dL in light of the ODYSSEY Outcomes Trial?

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?

In the setting of secondary post-ACS prevention, what is your trigger for moving beyond a statin/ezetimibe combination to a PCSK9 inhibitor?

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

From a medical cardiologist’s perspective, which patient subgroups in your practice do you feel represent ideal candidates for deployment of PCSK9 inhibitors to lower LDL-C levels, based on the results of the ODYSSEY Outcomes and FOURIER Trials?

From a medical cardiologist’s perspective, which patient subgroups in your practice do you feel represent ideal candidates for deployment of PCSK9 inhibitors to lower LDL-C levels, based on the results of the ODYSSEY Outcomes and FOURIER Trials?

Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering?

Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering?

Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?

Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

In your interventional cardiology practice, which markers of risk, in the patient who has undergone a PCI, do you focus on to promote consideration for using a PCSK9 inhibitor?

Showing 121 - 132 of 162 results

Previous| 1... 10 | 11 | 12 ...14 |Next